Asia1 type multi-epitope recombinant vaccine of bovine foot-and-mouth disease viruses and preparation method thereof

Abstract

The invention discloses an Asia1 type multi-epitope recombinant vaccine of bovine foot-and-mouth disease viruses and a preparation method thereof. The recombinant vaccine comprises the following components: proteins coded by foot-and-mouth disease virus multi-epitope genes and the fusion genes of carrier proteins, and foot-and-mouth disease virus 3D proteins. The preparation method comprises the following steps: diluting the proteins expressed by the foot-and-mouth disease virus multi-epitope genes and the fusion genes of the carrier proteins and the foot-and-mouth disease virus 3D proteins, mixing the diluted proteins uniformly, adding an adjuvant into the mixture to emulsify the mixture. Animal models and animal immune effect experiments show that the bovine Asia1 epitope recombinant vaccine can make comprehensive immune protective response, can induce injected and immunized bovine and guinea pigs to generate high level neutralizing antibodies, and can also induce cell immune response, so the recombinant vaccine can effectively protect animals against the virulent attack of the foot-and-mouth disease viruses.

Description

technical field [0001] The invention relates to an animal recombinant vaccine, in particular to a bovine foot-and-mouth disease virus Asia1 type multi-epitope recombinant vaccine and a preparation method thereof, belonging to the field of animal foot-and-mouth disease virus recombinant vaccines. Background technique [0002] As a major animal disease, foot-and-mouth disease not only seriously threatens the healthy development of animal husbandry, but also causes a series of social problems such as people's worries about food safety. Vaccine immunization is still one of the main means to effectively prevent and control FMD. However, most of the currently used vaccines are inactivated vaccines developed from pathogens. The production of such vaccines not only requires a high-level biosafety production workshop to prevent pathogens from escaping, but also requires a distinction between vaccine immunity and naturally infected animals. In addition, incomplete virus inactivation ...

AI Technical Summary

Problems solved by technology

However, the large-scale animal experiments all ended in failure (the protection rate of the virus attack did not reach the national standard), mainly because the small molecule antigens developed could not stimulate the body to produce a protective level of neutralizing antibodies, and some even could produce a certain level of protection. Antibodies, but the duration is short, which cannot meet the needs of epidemic prevention and control

In addition, the developed virus particle-like capsid protein can induce the body to produce high-titer protective antibodies, and immunized animals can resist the challenge of homologous viruses, but the low yield and high cost of the antigen limit the application of the vaccine

Recently, people have increased the immunogenicity of vaccines by increasing T cell epitopes and foreign carrier proteins to enhance antigen presentation capabilities, increase molecular ...

Images